111, Inc. Announces Establishment of the Special Committee
SHANGHAI, Sept. 28, 2026 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), comprising of three...
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
HONG KONG, Sept. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating...
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major...
Cloopen Group Holding Limited Announces Shareholders' Approval of Merger Agreement
BEIJING, Sept. 24, 2026 /PRNewswire/ -- Cloopen Group Holding Limited (OTC: RAASY) ("Cloopen" or the "Company"), today announced that at an extraordinary general meeting of shareholders (the "EGM") held today, the Company's shareholders voted in...
Baozun Announces US$10 million Share Repurchase Program
SHANGHAI, Sept. 24, 2026 /PRNewswire/ -- Baozun Inc. (Nasdaq: BZUN and HKEX: 9991) ("Baozun", the "Company" or the "Group"), a leading brand e-commerce solution provider and digital commerce enabler in China, today announced that the board of...
Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction
Primary Endpoint Achieved in CBL-0202DD Phase 2 Trial—CBL-514 delivered statistically significant pain reduction across both FAS and PP populations compared with placebo. Expansion Opportunity Beyond Dercum's Disease—Study findings support the...
Robo.ai Inc. Announces Results of Extraordinary General Meeting
DUBAI, UAE, Sept. 23, 2026 /PRNewswire/ -- Robo.ai Inc. (Nasdaq: AIIO) (the "Company"), a UAE-based, U.S.-listed company, today announced that each of the proposed resolutions submitted for shareholder approval as set forth in the notice of...
GIGABYTE Announces AORUS GeForce RTX™ 5060 ARI Edition Graphics Card is Available
TAIPEI, Sept. 22, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, announces the availability of the AORUS GeForce RTX™ 5060 ARI Edition graphics card, featuring an anime-inspired and performance-focused design for mainstream...
KT&G Announces KRW 360 Billion Share Buyback and Retirement to Enhance Shareholder Value
KT&G to purchase 2.07 million shares from Sept. 23 and retire all shares upon completion of the buyback H1 operating profit rises 22.6% YoY; new shareholder return policy slated for Q4 SEOUL, South Korea, Sept. 22, 2026 /PRNewswire/ -- KT&G...
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing...